COLL

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.

Wall Street analysts forecast COLL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COLL is 47.33 USD with a low forecast of 46.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Collegium Pharmaceutical Inc revenue for the last quarter amounts to 209.36M USD, increased 31.42 % YoY.

Collegium Pharmaceutical Inc. EPS for the last quarter amounts to 0.84 USD, increased 211.11 % YoY.

Collegium Pharmaceutical Inc (COLL) has 357 emplpoyees as of January 06 2026.

Today COLL has the market capitalization of 1.44B USD.